Loading
Qurient is a South Korean biotechnology company in Seongnam that leads two cancer trials in OnCo, testing the selective CDK7 inhibitor Q901 and the Axl/Mer/CSF1R inhibitor Q702, each with pembrolizumab, in advanced solid tumours.
Qurient is a company based in Seongnam, South Korea (Wikidata Q30253835; no website is recorded there, so none is given here). ClinicalTrials.gov classes it as an industry sponsor, with Merck Sharp & Dohme as collaborator on the pembrolizumab combinations. It leads two phase 1/2 trials recorded in OnCo: NCT05394103 (Q901, a highly selective CDK7 inhibitor, alone and with pembrolizumab in selected advanced solid tumours) and NCT05438420 (Q702, an oral Axl/Mer/CSF1R tyrosine kinase inhibitor, with pembrolizumab, recorded under cervical cancer). Both compounds are its own, the basis for the biotech type.
Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.
Shares Pembrolizumab and the tag wave5-sponsor.
Shares CSF1R, Small-molecule kinase inhibitors.
Shares CSF1R, Small-molecule kinase inhibitors.
Shares CSF1R, Small-molecule kinase inhibitors.
Shares CSF1R, Small-molecule kinase inhibitors.
Shares CSF1R, Small-molecule kinase inhibitors.
Shares CSF1R, Pembrolizumab.